Next Article in Journal
Linking Extracellular Matrix Agrin to the Hippo Pathway in Liver Cancer and Beyond
Previous Article in Journal
Elevated Polyamines in Saliva of Pancreatic Cancer
Previous Article in Special Issue
MYC Regulates α6 Integrin Subunit Expression and Splicing Under Its Pro-Proliferative ITGA6A Form in Colorectal Cancer Cells
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessReview
Cancers 2018, 10(2), 44;

Integrin Inhibitors in Prostate Cancer

Department of Pharmaceutical Sciences, School of Pharmacy, University of Puerto Rico, Medical Sciences Campus, San Juan, PR 00936, USA
University of Puerto Rico Comprehensive Cancer Center, Medical Sciences Campus, San Juan, PR 00936, USA
Author to whom correspondence should be addressed.
Received: 21 November 2017 / Revised: 12 January 2018 / Accepted: 19 January 2018 / Published: 6 February 2018
(This article belongs to the Special Issue Integrins in Cancer)
Full-Text   |   PDF [429 KB, uploaded 6 February 2018]   |  


Prostate cancer (PCa) is the most frequently diagnosed cancer and the third highest cause of cancer-related deaths in men in the U.S. The development of chemotherapeutic agents that can bind PCa tumor cells with high specificity is critical in order to increase treatment effectiveness. Integrin receptors and their corresponding ligands have different expression patterns in PCa cells. They have been identified as promising targets to inhibit pathways involved in PCa progression. Currently, several compounds have proven to target specific integrins and their subunits in PCa cells. In this article, we review the role of integrins inhibitors in PCa and their potential as therapeutic targets for PCa treatments. We have discussed the following: natural compounds, monoclonal antibodies, statins, campothecins analog, aptamers, d-aminoacid, and snake venom. Recent studies have shown that their mechanisms of action result in decrease cell migration, cell invasion, cell proliferation, and metastasis of PCa cells. View Full-Text
Keywords: Gleditsia sinensis; d-pinitol; Abituzumab; d-aminoacid; Contortrostatin; α2β1; αvβ3; metastasis; PC3; 22RV1 Gleditsia sinensis; d-pinitol; Abituzumab; d-aminoacid; Contortrostatin; α2β1; αvβ3; metastasis; PC3; 22RV1

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Juan-Rivera, M.C.; Martínez-Ferrer, M. Integrin Inhibitors in Prostate Cancer. Cancers 2018, 10, 44.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top